First patient dosed in Opti-GAIN, a first-in-human Phase I/II clinical trial of CTx001 in Geographic Atrophy secondary to AMD CTx001 is an investigational AAV-based gene therapy designed to deliver ...
First patient dosed in Opti-GAIN, a first-in-human Phase I/II clinical trial of CTx001 in Geographic Atrophy secondary to AMD Complement Therapeutics GmbH (CTx), a clinical-stage biotechnology company ...
German company Complement Therapeutics, which has a research laboratory at Stevenage Bioscience Catalyst, reports that the first patient has been dosed in a clinical trial of its trailblazing ...
aRheumatology Service, Maimonides Institute of Biomedical Research of Cordoba (IMIBIC), Reina Sofia University Hospital, University of Córdoba, Córdoba, Spain Antiphospholipid syndrome is a rare ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results